World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website https://www.wjon.org

Original Article

Volume 15, Number 3, June 2024, pages 454-462

Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice

**Table 1.** Clinical-Pathological and Biological Characteristics of the Patients (N = 318)
		N	Frequency (relative %)
Min: minimum; Max: maximum; HR: hormone receptors; PR: progesterone receptor; CNS: central nervous system.
Age, median (Min; Max)	56 years (27; 88)
Origin	Capital (Montevideo)	129	40.6
	Interior of the country	189	59.4
Menopausal status	Postmenopausal	201	63.2
	Premenopausal	86	27.0
	Perimenopausal	16	5.0
	No data	15	4.7
Institution of origin	Private	265	83.3
	Public	53	16.7
HR/PR	Positive	192	60.4
	Negative	85	26.7
	No data	41	12.9
Stage	I	0	0
	II	1	0.3
	III	5	1.6
	IV	309	97.2
	No data	3	0.9
Metastasis site	Bone	182	57.2
	Lung	96	30.2
	Liver	93	29.2
	Cutaneous/subcutaneous	38	11.9
	CNS	18	5.7
	Other	82	25.8
	No data	7	2.2
Performance status	0	212	76.0
	1	42	15.1
	No data	25	9.0

Table 1. Clinical-Pathological and Biological Characteristics of the Patients (N = 318)

Frequency (relative %)

Min: minimum; Max: maximum; HR: hormone receptors; PR: progesterone receptor; CNS: central nervous system.

Age, median (Min; Max)

56 years (27; 88)

Origin

Capital (Montevideo)

129

40.6

Interior of the country

189

59.4

Menopausal status

Postmenopausal

201

63.2

Premenopausal

27.0

Perimenopausal

5.0

No data

4.7

Institution of origin

Private

265

83.3

Public

16.7

HR/PR

Positive

192

60.4

Negative

26.7

No data

12.9

Stage

0.3

III

1.6

309

97.2

No data

0.9

Metastasis site

Bone

182

57.2

Lung

30.2

Liver

29.2

Cutaneous/subcutaneous

11.9

CNS

5.7

Other

25.8

No data

2.2

Performance status

212

76.0

15.1

No data

9.0

**Table 2.** OS Based on Metastasis Site (N = 318)
Topography of metastases	Number	Events	Median survival (months)	P
*P < 0.05. OS: overall survival; CNS: central nervous system.
Bone metastases				0.460
No	129	66	27.6
Yes	179	101	29.0
Liver metastases				0.120
No	222	115	30.1
Yes	93	55	22.5
CNS metastases				0.022*
No	297	158	29.1
Yes	18	12	6.9
Cutaneous-subcutaneous metastases				0.029*
No	271	140	29.4
Yes	37	27	17.2
Lung metastases				0.006*
No	216	109	30.1
Yes	93	58	21.4

Table 2. OS Based on Metastasis Site (N = 318)

Topography of metastases

Number

Events

Median survival (months)

*P < 0.05. OS: overall survival; CNS: central nervous system.

Bone metastases

0.460

129

27.6

Yes

179

101

29.0

Liver metastases

0.120

222

115

30.1

Yes

22.5

CNS metastases

0.022*

297

158

29.1

Yes

6.9

Cutaneous-subcutaneous metastases

0.029*

271

140

29.4

Yes

17.2

Lung metastases

0.006*

216

109

30.1

Yes

21.4

**Table 3.** Multivariate Analysis of Factors Associated With OS
	Crude HR	CI	P	Adjusted HR	CI	P
*P < 0.05. OS: overall survival; CNS: central nervous system; HR: hazard ratio; CI: confidence interval.
Menopausal status
Premenopausal	1			1
Perimenopausal	2.05	1.02 - 4.12	0.045*	1.56	0.60 - 4.06	0.359
Postmenopausal	1.15	0.80 - 1.66	0.45	0.93	0.62 - 1.41	0.743
HR status
Negative	1			1
Positive	0.57	0.40 - 0.80	0.001*	0.55		0.003*
Performance status
0	1			1
1	1.68	1.12 - 2.53	0.012*	1.79		0.016*
CNS metastasis
No	1			1
Yes	1.97	1.10 - 3.54	0.024*	1.00		0.999
Lung metastasis
No	1			1
Yes	1.56	1.13 - 2.15	0.006*	1.73		0.004*
Cutaneous-subcutaneous metastasis
No	1			1
Yes	1.58	1.05 - 2.40	0.030*	2.13		0.004*
Origin
Private	1			1
Public	1.63	1.12 - 2.38	0.011*	2.08		0.001*

Table 3. Multivariate Analysis of Factors Associated With OS

Crude HR

Adjusted HR

*P < 0.05. OS: overall survival; CNS: central nervous system; HR: hazard ratio; CI: confidence interval.

Menopausal status

Premenopausal

Perimenopausal

2.05

1.02 - 4.12

0.045*

1.56

0.60 - 4.06

0.359

Postmenopausal

1.15

0.80 - 1.66

0.45

0.93

0.62 - 1.41

0.743

HR status

Negative

Positive

0.57

0.40 - 0.80

0.001*

0.55

0.003*

Performance status

1.68

1.12 - 2.53

0.012*

1.79

0.016*

CNS metastasis

Yes

1.97

1.10 - 3.54

0.024*

1.00

0.999

Lung metastasis

Yes

1.56

1.13 - 2.15

0.006*

1.73

0.004*

Cutaneous-subcutaneous metastasis

Yes

1.58

1.05 - 2.40

0.030*

2.13

0.004*

Origin

Private

Public

1.63

1.12 - 2.38

0.011*

2.08

0.001*